Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 54
Filter
1.
Mult Scler ; 23(11): 1479-1487, 2017 Oct.
Article in English | MEDLINE | ID: mdl-28273762

ABSTRACT

BACKGROUND: The importance of the innate immune system in multiple sclerosis (MS) is increasingly recognized and the role of natural killer (NK) cells in controlling autoimmunity may be an important modulator of disease activity. OBJECTIVE: To examine NK subsets in MS patients on different treatments and to evaluate the role of NK subsets as indicators for disease activity. METHODS: We measured NK subset levels in blood obtained from 110 relapsing-remitting MS patients. Patients were either off treatment or on treatment with natalizumab, fingolimod, glatiramer acetate or beta-interferon. Disease activity was defined according to 'No Evidence of Disease Activity' (NEDA) criteria within an observation period of up to 2.4 years. The mean NK subset levels were compared among treatment groups using multivariate analysis of variance (ANOVA) and association analysis with disease activity performed using multi-factor logistic regression. RESULTS: Our analysis revealed differences in NK cells and subsets on treatment compared to off treatment ( p < 0.0005). A high proportion of bright NK cells were significantly associated with stable magnetic resonance imaging (MRI) imaging after adjusting for treatment effects ( p < 0.05). CONCLUSION: The independent association of NK subsets with MRI stability needs to be confirmed in prospective studies to test their usefulness in predicting disease activity in MS patients.


Subject(s)
Disease Progression , Killer Cells, Natural , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/diagnostic imaging , Adult , Aged , Australia , Cohort Studies , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Young Adult
2.
Eye (Lond) ; 30(4): 632-4, 2016 Apr.
Article in English | MEDLINE | ID: mdl-26742869

ABSTRACT

AIMS: This brief report of four cases of conjunctivitis caused by Raoultella planticola provides a description of possibly the first documented cases of this eye infection. METHODS: The laboratory database and medical records were used to trace all the R. planticola-positive conjunctival swabs obtained in our institution. Four cases were identified and available relevant information was obtained. RESULTS: This organism causes a non-specific purulent conjunctivitis that seems to have a benign course and tends to be responsive to a topical fluoroquinolone. CONCLUSIONS: The possibility of atypical organisms must be considered when managing infective conjunctivitis. Conjunctival swabs should be obtained and topical treatment switched when initial empirical therapy fails.


Subject(s)
Conjunctiva/microbiology , Conjunctivitis, Bacterial/microbiology , Enterobacteriaceae Infections/microbiology , Enterobacteriaceae/isolation & purification , Eye Infections, Bacterial/microbiology , Administration, Topical , Adolescent , Aged , Aged, 80 and over , Anti-Bacterial Agents/therapeutic use , Ciprofloxacin/therapeutic use , Conjunctivitis, Bacterial/diagnosis , Conjunctivitis, Bacterial/drug therapy , Enterobacteriaceae Infections/diagnosis , Enterobacteriaceae Infections/drug therapy , Eye Infections, Bacterial/diagnosis , Eye Infections, Bacterial/drug therapy , Female , Humans , Male , Microbial Sensitivity Tests
3.
Epidemiol Infect ; 143(14): 3110-3, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25697304

ABSTRACT

Although Malta is historically linked with the zoonosis brucellosis, there had not been a case of the disease in either the human or livestock population for several years. However, in July 2013 a case of human brucellosis was identified on the island. To determine whether this recent case originated in Malta, four isolates from this case were subjected to molecular analysis. Molecular profiles generated using multilocus sequence analysis and multilocus variable number tandem repeat for the recent human case isolates and 11 Brucella melitensis strains of known Maltese origin were compared with others held on in-house and global databases. While the 11 isolates of Maltese origin formed a distinct cluster, the recent human isolation was not associated with these strains but instead clustered with isolates originating from the Horn of Africa. These data was congruent with epidemiological trace-back showed that the individual had travelled to Malta from Eritrea. This work highlights the potential of using molecular typing data to aid in epidemiological trace-back of Brucella isolations and assist in monitoring of the effectiveness of brucellosis control schemes.


Subject(s)
Brucella melitensis/classification , Brucella melitensis/genetics , Brucellosis/epidemiology , Minisatellite Repeats , Multilocus Sequence Typing , Travel , Africa , Brucella melitensis/isolation & purification , Humans , Malta/epidemiology , Molecular Epidemiology
6.
Dig Liver Dis ; 37(7): 501-8, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15975537

ABSTRACT

BACKGROUND: Several tests have been proposed for evaluating dyspeptic symptoms and their relationship to the underlying gastric disease. Serum pepsinogens and gastrin-17 are known to be useful biomarkers for the detection of gastric pathologies. AIM: To evaluate the capability of screening dyspeptic patients in the primary care by analyses of serum pepsinogens I (sPGI) and II (sPGII), gastrin-17 (sG-17) and the IgG anti-Helicobacter pylori antibodies (IgG-Hp). PATIENTS AND METHODS: Three hundred and sixty-two consecutive patients with dyspeptic symptoms (208 females, mean age 50.6 +/- 16 years, range 18-88 years) referred by general practitioners for upper gastrointestinal endoscopy were enrolled. A blood sample was taken from each subject for IgG-Hp, sPGI, sPGII and sG-17 analyses. RESULTS: Two hundred and eighty-seven patients had a complete screening; of these, 132 resulted positive for Hp infection. Patients with atrophic chronic gastritis showed significantly lower serum pepsinogen I levels and sPGI/sPGII ratio than patients with non-atrophic chronic gastritis. Moreover, by calculating the values of sPGI by sG-17 and sG-17 by sPGII/sPGI, subjects with atrophic chronic gastritis could be distinguished from those with non-atrophic chronic gastritis and from those with normal mucosa, respectively. sG-17 levels were found to be a useful biomarker for the detection of antral atrophic gastritis, while the combination of sPGI, the sPGI/sPGII ratio and sG-17 was found effective in identifying corpus atrophy. CONCLUSION: A panel composed of PGI, PGII, G-17 and IgG-Hp could be used as a first approach in the 'test and scope' and/or 'test and treat' strategy in the primary care management of dyspeptic patients.


Subject(s)
Antibodies, Bacterial/analysis , Dyspepsia/blood , Gastrins/blood , Gastritis/diagnosis , Helicobacter pylori/immunology , Pepsinogen A/blood , Pepsinogen C/blood , Adult , Aged , Aged, 80 and over , Chronic Disease , Dyspepsia/etiology , Female , Gastritis/complications , Gastritis/microbiology , Gastroscopy , Humans , Immunoglobulin G/immunology , Male , Mass Screening , Middle Aged , Primary Health Care
7.
Minerva Chir ; 58(3): 405-8, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12955065

ABSTRACT

We report a patient in whom heterotopic pancreatic tissue was found within the ampulla and treated by ampullectomy. Only 16 cases of pancreatic tissue located at the ampulla of Vater have been reported in the literature and pancreaticoduodenectomy has been performed in more than half the cases because malignancy was suspected preoperatively, reflecting a rather aggressive surgical attitude. An accurate preoperative evaluation thus appears decisive to avoid unnecessary radical surgery. Endoscopic treatment of ampullary tumors is emerging as a viable alternative to surgical treatment. Local surgical excision is a reasonable option to endoscopic treatment. The possibility of heterotopic pancreatic tissue, though rare, should be included in the differential diagnosis of papillary tumors. Histologic confirmation (frozen or delayed) is mandatory before attempting such major surgery.


Subject(s)
Ampulla of Vater , Choristoma , Common Bile Duct Diseases , Pancreas , Aged , Choristoma/diagnosis , Choristoma/surgery , Common Bile Duct Diseases/diagnosis , Common Bile Duct Diseases/surgery , Female , Humans , Pancreas/surgery
8.
Scand J Gastroenterol ; 38(12): 1223-7, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14750641

ABSTRACT

BACKGROUND: Relatives of patients with gastric cancer are at increased risk of developing this disease, especially if they are infected by Helicobacter pylori. Moreover, H. pylori-related atrophic gastritis and hypochlorhydria are well-documented risk factors for noncardia gastric cancer. Serum pepsinogen I (sPGI) and II (sPGII) levels are low in this condition. The aim of our study was to assess by means of a 'Gastropanel' blood test, including sPGI, sPGII, gastrin-17 (G-17) and antibodies anti-H. pylori (IgG-Hp). both functional and morphological features of gastric mucosa in Hp + ve subjects with a family history of gastric cancer. MATERIALS AND METHODS: Twenty-five Hp + ve subjects consecutively referred to our department for gastrointestinal complaints, selected as first-degree relatives of patients suffering from gastric cancer, were enrolled in the study and then matched for sex and age with 25 dyspeptic and Hp + ve subjects with no family history of gastric neoplasia. Blood samples were taken for determination of gastropanel in all patients; in addition, antibodies against CagA were analysed. RESULTS: No statistically significant differences were detected between the two groups as regards alcohol consumption, coffee intake and smoking habits. Mean sPGI levels in Group A (83.4 +/- 58.4 microg/L) were significantly lower than those in Group B (sPGI 159.5 +/- 80.6 microg/L; P < 0.0001) as well as sPGII (12.5 microg/L = 6.24 versus 20.6 +/- 58 microg/L; P < 0.006). No statistical difference was found between the two groups in relation to G-17 levels, IgG-Hp titres and antibodies against CagA. CONCLUSION: First-degree relatives of patients with noncardia gastric cancer affected by H. pylori infection present lower sPGI and sPGII levels, possibly due to the increased frequency of atrophic lesions in these patients.


Subject(s)
Helicobacter Infections/complications , Helicobacter pylori , Stomach Neoplasms/diagnosis , Stomach Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Antigens, Bacterial/immunology , Bacterial Proteins/immunology , Biomarkers/blood , Dyspepsia/microbiology , Family Health , Female , Gastrins/blood , Gastritis, Atrophic/complications , Gastritis, Atrophic/microbiology , Genetic Predisposition to Disease , Helicobacter pylori/immunology , Humans , Immunoglobulin G/blood , Male , Middle Aged , Pepsinogen A/blood , Pepsinogen C/blood , Stomach Neoplasms/microbiology
9.
Aliment Pharmacol Ther ; 16(10): 1723-31, 2002 Oct.
Article in English | MEDLINE | ID: mdl-12269964

ABSTRACT

BACKGROUND: Helicobacter pylori infection induces atrophic body gastritis, but the long-term effect of its cure on body atrophy is unclear. AIM: To investigate the long-term effects of H. pylori cure on gastric morpho-functional parameters in patients with atrophic body gastritis. METHODS: Forty patients with atrophic body gastritis were cured of H. pylori infection. Gastroscopy with biopsies, gastrin and pepsinogen I levels and basal and stimulated acid secretion were evaluated before and 6-12 months after treatment. RESULTS: At eradication assessment (6-12 months), in eight of the 40 patients, body atrophy was no longer observed, whereas in 32 of the 40 it remained substantially unchanged (2.03 +/- 0.12 vs. 1.83 +/- 0.15). In the eight patients with reversed body atrophy, gastrinaemia decreased significantly with respect to pre-treatment values (265 +/- 59.9 pg/mL vs. 51.8. +/- 6.04 pg/mL), and basal and stimulated acid secretion increased significantly after cure. In the 32 patients still presenting body atrophy, gastrinaemia was similar topre-treatment values (457 +/- 76.04 pg/mL vs. 335.1 +/- 58.8 pg/mL). At follow-up (21-25 and 32-70 months), the eight patients with reversed body atrophy continued with normal gastrinaemia (35.3 +/- 10.1 pg/mL vs. 38.5 +/- 8.8 pg/mL), but in the 19 patients with continued atrophy, both corporal atrophy and intestinal metaplasia remained substantially unchanged. CONCLUSIONS: Following successful treatment in patients with atrophic body gastritis and H. pylori infection, long-term histological investigations are crucial in order to detect reversed body damage or to confirm continued body atrophy.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Gastritis, Atrophic/microbiology , Helicobacter Infections/drug therapy , Helicobacter pylori , Adult , Aged , Female , Follow-Up Studies , Gastric Acid/metabolism , Gastric Mucosa/pathology , Gastrins/blood , Gastritis, Atrophic/metabolism , Gastritis, Atrophic/pathology , Gastroscopy , Helicobacter Infections/metabolism , Humans , Male , Middle Aged , Pepsinogen A/blood , Prospective Studies
10.
Aliment Pharmacol Ther ; 16(3): 507-14, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11876704

ABSTRACT

BACKGROUND: It has been reported that 50% of patients with atrophic body gastritis have positive Helicobacter pylori antibody titres only. In atrophic body gastritis, a decrease in H. pylori antibodies after eradication treatment has been reported, suggesting that serology may indicate an active H. pylori infection. AIM: To investigate the time course of H. pylori antibodies and gastric inflammation after eradication treatment in patients with atrophic body gastritis, and to determine whether serology alone can be considered as a valid tool to assess the efficacy of eradication treatment in patients with atrophic body gastritis. METHODS: Twenty-seven patients with atrophic body gastritis (12 serologically H. pylori-positive only, ABG-S+; 15 H. pylori-positive at histology and serology, ABG-H+) were included in the treatment group, and 17 patients (all ABG-S+) in the no treatment group. All patients had gastroscopy plus biopsies evaluated according to the updated Sydney system and H. pylori immunoglobulin G determination: in the treatment group, at baseline and 6 and 24 months after eradication (bismuth-based triple regimens); in the no treatment group, at baseline and after 3 years. RESULTS: In the treatment group, in ABG-S+ patients, H. pylori antibodies decreased significantly 6 months after treatment [37.5 U/mL (16-100 U/mL) vs. 15 U/mL (0--100 U/mL), P < 0.01], but 2 years after treatment no further decrease occurred. In addition, in ABG-H+ patients, a significant decrease in H. pylori antibodies occurred 6 months after treatment [45 U/mL (12.5-100 U/mL) vs. 31 U/mL (0-65 U/mL), P < 0.01], but a further decrease was also observed 2 years after treatment [20 U/mL (0-56 U/mL), P < 0.01]. In ABG-S+ patients, no correlation was observed between the H. pylori antibodies and gastric inflammation score, whereas, in the ABG-H+ group, this correlation was extremely significant (r=0.5991, P < 0.0001). In the no treatment group, at follow-up, a significant decrease in H. pylori antibodies was observed [26 U/mL (15-100 U/mL) vs. 22 U/mL (0-53 U/mL), P < 0.05], but the gastric body inflammation remained unchanged. CONCLUSIONS: This study shows that, in ABG-S+ patients after eradication treatment, serology does not keep in step with gastric inflammation. This suggests that, in patients with atrophic body gastritis, serology alone may not be valid for the assessment of the efficacy of eradication treatment.


Subject(s)
Gastritis, Atrophic/drug therapy , Gastritis, Atrophic/immunology , Helicobacter Infections/drug therapy , Helicobacter Infections/immunology , Helicobacter pylori/immunology , Acute Disease , Adult , Aged , Antacids/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bismuth/therapeutic use , Chronic Disease , Drug Therapy, Combination , Female , Gastritis, Atrophic/etiology , Gastritis, Atrophic/microbiology , Helicobacter Infections/complications , Helicobacter pylori/drug effects , Helicobacter pylori/physiology , Humans , Inflammation/complications , Inflammation/drug therapy , Inflammation/immunology , Male , Middle Aged , Serologic Tests , Time Factors
11.
Eur J Gastroenterol Hepatol ; 13(12): 1449-56, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11742193

ABSTRACT

BACKGROUND/AIMS: In the presence of atrophic body gastritis, gastric carcinoid develops from gastric-body mucosa enterochromaffin-like cells. Few data exist on the prevalence of enterochromaffin-like dysplastic lesions in atrophic body gastritis patients and their presumed risk of evolution to carcinoid has never been assessed prospectively in humans. The aim of the present study was to investigate the prevalence and incidence of dysplastic and neoplastic enterochromaffin-like cell lesions in a consecutive series of patients with atrophic body gastritis. METHODS: A total of 130 atrophic body gastritis patients at diagnosis and 96 atrophic body gastritis patients at follow-up (median 30 months) underwent gastroscopy with multiple biopsies and fasting gastrinaemia evaluation. In patients with enterochromaffin-like cell dysplasia, a more detailed bioptic sampling at follow-up was performed. RESULTS: Of the 130 atrophic body gastritis patients, only one (0.7%) had a gastric carcinoid polyp, whereas enterochromaffin-like cell dysplasia was found in five patients (3.8%). At follow-up only one out of the 96 atrophic body gastritis patients (1%) was diagnosed as having a carcinoid polyp at 41 months. Enterochromaffin-like cell dysplasia was present in four additional patients (4.2%). Two atrophic body gastritis pernicious anaemia patients with enterochromaffin-like cell dysplasia developed a gastric carcinoid in the follow-up. Among nine atrophic body gastritis patients with enterochromaffin-like cell dysplasia, the incidence of carcinoid tumour was 22% compared to 1.1% of atrophic body gastritis patients without dysplasia (odds ratio: 26.00; 95% confidence interval: 2.089-323.52). During the follow-up, fasting gastrin levels increased significantly only in atrophic body gastritis patients with enterochromaffin-like cell dysplasia (mean 677.4 +/- 66.1 vs 1112.2 +/- 185.6; P = 0.0287). CONCLUSION: This study provides the first clinical evidence that, in hypergastrinaemic atrophic body gastritis patients, enterochromaffin-like cell dysplasia carries a markedly increased risk for development of type I gastric carcinoid. This suggests that a more detailed endoscopic/bioptic procedure in this subgroup of atrophic body gastritis patients is able to detect gastric carcinoid at an early stage.


Subject(s)
Carcinoid Tumor/pathology , Enterochromaffin-like Cells/pathology , Gastritis, Atrophic/pathology , Precancerous Conditions/pathology , Stomach Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Carcinoid Tumor/metabolism , Female , Follow-Up Studies , Gastrins/metabolism , Gastritis, Atrophic/metabolism , Humans , Immunohistochemistry , Male , Middle Aged , Odds Ratio , Precancerous Conditions/metabolism , Prevalence , Prospective Studies , Risk , Stomach Neoplasms/metabolism
12.
Mod Pathol ; 14(11): 1169-74, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11706080

ABSTRACT

Periampullary tumors in patients affected by Neurofibromatosis Type 1 (NF-1) are usually carcinoids or stromal tumors and, rarely, adenocarcinomas. We report a case of an adenocarcinoma of the ampulla of Vater in a 54-year-old woman with NF-1 admitted to the hospital with jaundice and undergoing pancreato-duodenectomy. Histologically, the resected specimen showed an adenocarcinoma of the ampulla as being a part of a complex atypical epithelial proliferation extended from the papilla to the mucosa of the duodenum and distal choledochus, islet-cell adenomatosis of the pancreas and multiple gastric, duodenal, jejunal stromal tumors. The ampullary and periampullary adenocarcinomas in NF-1 patients have peculiar features, suggesting a widespread predisposition to cancer development in periampullary tissues and requiring widely demolitive surgery. Moreover, they occur at a younger age than those occurring in non-NF-1 patients, may be associated with additional periampullary epithelial tumors, are often operable and may present long survival.


Subject(s)
Adenocarcinoma/pathology , Ampulla of Vater/pathology , Common Bile Duct Neoplasms/pathology , Neurofibromatosis 1/complications , Adenocarcinoma/complications , Common Bile Duct Neoplasms/complications , Female , Humans , Middle Aged
13.
Aliment Pharmacol Ther ; 15(11): 1753-61, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11683689

ABSTRACT

BACKGROUND: Recent studies have reported an association between iron deficiency anaemia and Helicobacter pylori. Helicobacter pylori could cause iron deficiency anaemia by altering iron absorption. We observed that most patients with Helicobacter pylori infection and iron deficiency anaemia present a chronic superficial pangastritis. AIM: To investigate whether Helicobacter pylori-positive patients with iron deficiency anaemia have peculiar histological and functional features when compared with non-anaemic Helicobacter pylori-positive subjects. PATIENTS: Fifty-one patients with iron deficiency anaemia, in whom chronic superficial Helicobacter pylori gastritis was the only gastrointestinal finding, and 103 non-anaemic Helicobacter pylori-positive controls were included in the study. Thirty-seven patients were randomly matched with 37 controls of the same sex and age. METHODS: Gastroscopy, with antral (n=3) and body (n=3) biopsies, was performed. Gastrin and pepsinogen I levels and antiparietal cell antibodies were evaluated. Intragastric pH was also measured. RESULTS: Gastritis involved the corporal mucosa in 90% of patients compared to 42.7% of controls (P < 0.0001). The mean inflammatory score in the gastric body was significantly higher among patients than in controls (2.2 vs. 0.6; P=0.012). Gastrin was significantly higher in patients than in controls (mean 60.2 vs. 29 pg/mL; P=0.0069). Intragastric pH was higher in patients than in controls (median 5.7 vs. 2; P=0.0026). CONCLUSIONS: These data suggest that patients with iron deficiency anaemia and Helicobacter pylori infection have a peculiar pattern of gastritis with corporal involvement and related changes in intragastric pH.


Subject(s)
Anemia, Iron-Deficiency/complications , Gastric Acid/metabolism , Gastric Mucosa/pathology , Gastritis/etiology , Helicobacter Infections/complications , Adolescent , Adult , Aged , Case-Control Studies , Chronic Disease , Female , Gastric Acidity Determination , Gastrins/analysis , Gastritis/microbiology , Gastritis/pathology , Gastroscopy , Helicobacter pylori/isolation & purification , Helicobacter pylori/pathogenicity , Humans , Hydrogen-Ion Concentration , Inflammation , Male , Middle Aged
14.
Helicobacter ; 6(3): 225-33, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11683925

ABSTRACT

BACKGROUND: Helicobacter pylori is involved in the induction of atrophic body gastritis (ABG). During the progression of atrophic gastritis the disappearance of H. pylori has been documented and in time serology is the only sign that indicates a previous infection. It has been shown that a positive serology, in ABG patients without histological evidence of infection, indicates an active H. pylori infection. AIM: To investigate in a population of patients with ABG the prevalence of H. pylori infection on the basis of histology and serology. PATIENTS: A total of 150 consecutive outpatients with atrophic body gastritis were diagnosed on the basis of a screening system. METHODS: All patients had a detailed assessment including measurement of specific anti-H. pylori antibodies, parietal cell antibodies, and fasting gastrin, gastroscopy with biopsies from gastric antrum and body. RESULTS: 24.6% of patients were histologically and serologically negative (Group A). 52.7% H. pylori was not detected on histology but IgG to H. pylori were in all these patients elevated (Group B). 22.6% of patients were found to be positive at histology in the corpus mucosa; all but one of these patients had elevated circulating IgG to H. pylori (Group C). Mean corporal atrophy score in Group B patients was statistically lower than in Group A patients (2.43 +/- 0.08 vs. 2.75 +/- 0.09; p <.05), but was statistically higher than in Group C patients (1.79 +/- 0.11; p <.001). Thus, in corporal mucosa a gradient of atrophy was shown: Group C < Group B < Group A. A similar gradient was observed for the presence of pernicious anemia being lowest in Group C 11.8% increasing to 45.6% in Group B and being highest in Group C 75.6%. A statistical correlation was obtained (r =.04791, p <.05) between the histological score of corporal atrophy and the titer of antibodies to parietal cells and an inverse correlation was obtained (r = -.2322, p <.0001) between the histological score of corporal atrophy and IgG to H. pylori. CONCLUSION: This study shows that two-thirds of ABG patients have evidence of H. pylori infection. This suggests that atrophic gastritis of the corpus is a spectrum of damage where H. pylori is a key agent able to induce gastric atrophic damage and also gastric autoimmunity.


Subject(s)
Antigens, Bacterial , Gastritis, Atrophic/microbiology , Helicobacter Infections/complications , Helicobacter pylori , Adult , Aged , Aged, 80 and over , Autoantibodies/analysis , Bacterial Proteins/blood , Female , Gastric Acid/metabolism , Gastrins/blood , Gastritis, Atrophic/pathology , Helicobacter Infections/epidemiology , Helicobacter Infections/pathology , Helicobacter pylori/immunology , Helicobacter pylori/isolation & purification , Humans , Immunoglobulin G/immunology , Male , Middle Aged , Parietal Cells, Gastric/immunology , Prevalence
15.
Ann Allergy Asthma Immunol ; 86(6): 665-70, 2001 Jun.
Article in English | MEDLINE | ID: mdl-11428740

ABSTRACT

BACKGROUND: Parameters for identifying eczematous children who could respond to an elimination diet are needed. In children with food allergy, duodenal IgE-containing cells are enhanced. OBJECTIVE: To determine the presence of duodenal mucosal IgE-positive cells in atopic dermatitis and to determine whether duodenal IgE-positive cells may identify eczematous children who will benefit from an elimination diet. METHODS: Thirty-one children with severe eczema underwent gastrointestinal endoscopy because of gastrointestinal symptoms and were treated with an elimination diet. A clinical score to skin lesions was given before and after diet. All subjects were skin-prick tested with food antigens and aeroallergens. Serum IgE levels were measured. Duodenal IgE-positive cells were investigated in 18 control subjects and in all eczematous children before diet. RESULTS: The number of duodenal IgE-positive cells in children with atopic dermatitis was significantly increased compared with that of control group (P < 0.001). Nineteen (61%) eczematous children improved on a few food diet. Diet-responsive children had significantly higher IgE-positive cells compared with both nondiet-responsive and controls. Positive predictive accuracy of duodenal IgE-positive cells was poor, whereas negative predictive accuracy was high at the cutoff level of 50 IgE-positive cells/10 visual fields. Diagnostic accuracy both of SPT reactions with foods and of food-specific serum IgE antibodies was poor. CONCLUSIONS: An intestinal IgE-mediated reaction occurred in children with severe atopic dermatitis who underwent intestinal endoscopy because of gastrointestinal symptoms. In these eczematous children, the number of IgE-positive cells in the duodenal mucosa might be helpful for excluding a positive response to the elimination diet.


Subject(s)
Dermatitis, Atopic/immunology , Duodenum/immunology , Feeding Behavior , Immunoglobulin E/analysis , Adolescent , Child , Child, Preschool , Duodenum/cytology , Female , Humans , Immunoglobulin E/blood , Infant , Intestinal Mucosa/cytology , Intestinal Mucosa/immunology , Male , Predictive Value of Tests , Skin Tests
16.
Arch Dis Child ; 84(5): 419-22, 2001 May.
Article in English | MEDLINE | ID: mdl-11316688

ABSTRACT

AIMS: To compare two strategies for the eradication of Helicobacter pylori infection. METHODS: Groups 1 and 2 each consisted of 75 consecutive patients. Patients in group 1 were treated with two antibiotics based on antibiotic susceptibility testing; those in group 2 received amoxycillin and clarithromycin for eight days, together with either ranitidine or omeprazole. Eradication rate was assessed in both groups six months after treatment. RESULTS: In group 1, H pylori grew in culture in 63/75 cases. Susceptibility testing showed that 35/63 isolates were resistant to metronidazole, 10/63 to clarithromycin, 2/63 to ampicillin, 1/63 to tetracycline, and 5/63 to both clarithromycin and metronidazole. In group 1 the infection was eradicated in 96% of the initial 75 subjects, and in 98% of the subjects treated according to the antibiotic assay (62/63). As two patients were lost at follow up the overall eradication rate was 99%. In group 2, eradication was achieved in 61/75 subjects (81%). This was significantly lower than the percentage of eradication observed in group 1 (81% versus 99%). CONCLUSIONS: Antibiotic susceptibility tests are useful in childhood as a very high percentage of subjects are cured. This approach is costly, but selective antibiotic treatment contributes to limit further development of antibiotic resistance, and money is saved in terms of reinvestigation and further repeated treatments.


Subject(s)
Amoxicillin/therapeutic use , Clarithromycin/therapeutic use , Drug Therapy, Combination/therapeutic use , Helicobacter Infections/drug therapy , Helicobacter pylori/drug effects , Adolescent , Anti-Ulcer Agents/therapeutic use , Child , Child, Preschool , Drug Resistance, Microbial , Female , Humans , Infant , Male , Omeprazole/therapeutic use , Ranitidine/therapeutic use , Treatment Outcome
17.
Gastrointest Endosc ; 53(4): 443-8, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11275884

ABSTRACT

BACKGROUND: Body-predominant atrophic gastritis is considered a risk factor for gastric cancer and carcinoid. Timing of follow-up for patients with this disorder has not been defined. This study was undertaken to determine the optimal time for the first endoscopic/histologic follow-up in patients with body-predominant atrophic gastritis. METHODS: Forty-two patients with body-predominant atrophic gastritis were randomly assigned to 1 of 2 follow-up intervals: group A (n = 22) at 24 months and group B (n = 20) at 48 months. At baseline and follow-up patients underwent gastroscopy at which biopsies were obtained from the antrum and body for histopathology and evaluation for enterochromaffin-like cells. RESULTS: In group A patients, 2 antral hyperplastic polyps (9.1%) were present at baseline and 4 antral hyperplastic polyps (18.2%) were found at follow-up. In group B patients, baseline gastroscopy revealed 2 antral hyperplastic polyps (10%) and follow-up 2 antral hyperplastic polyps (10%) and 1 carcinoid tumor (5%) in the body. Atrophy and intestinal metaplasia scores in gastric body and antral mucosa in both groups did not change significantly between baseline and follow-up, except an increase in antral mucosa atrophy in group B patients (p = 0.02) was revealed. CONCLUSIONS: The results of this study indicate that performing the first follow-up in patients with body-predominant atrophic gastritis need not be earlier than at 4 years after diagnosis. This interval is satisfactory for detection of potential neoplastic lesions.


Subject(s)
Carcinoid Tumor/diagnosis , Gastritis, Atrophic/complications , Gastroscopy/methods , Stomach Neoplasms/diagnosis , Adult , Aged , Anemia, Pernicious/diagnosis , Biopsy , Carcinoid Tumor/complications , Carcinoid Tumor/pathology , Enterochromaffin-like Cells , Female , Follow-Up Studies , Gastric Mucosa , Gastrins/analysis , Helicobacter Infections/microbiology , Helicobacter pylori/isolation & purification , Humans , Male , Middle Aged , Pepsinogen A/analysis , Polyps/diagnosis , Prospective Studies , Pyloric Antrum , Random Allocation , Stomach Neoplasms/complications , Stomach Neoplasms/pathology , Time Factors
18.
Am J Obstet Gynecol ; 183(3): 588-92, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10992178

ABSTRACT

OBJECTIVE: We sought to evaluate the efficacy of postoperative administration of monophasic, combined, low-dose oral contraceptives on endometrioma recurrence and on persistence-recurrence of associated pain symptoms after laparoscopic treatment of moderate-to-severe endometriosis. STUDY DESIGN: In a prospective, randomized trial 70 patients who were not attempting to conceive, aged 20 to 35 years, underwent laparoscopic excision of ovarian endometriomas, followed by either postoperative administration of low-dose cyclic oral contraceptives for 6 months or no treatment on the basis of a computer-generated sequence. At 3 and 6 months after surgery and then at 6-month intervals, both groups underwent ultrasonographic examination for possible evidence of endometrioma recurrence and for evaluation of the absence, persistence, or recurrence of pain symptoms. RESULTS: Two patients in the oral contraceptive group did not complete the study. After a mean follow-up of 22 months (range, 12-48 months), there were 2 (6.1%) endometrioma recurrences in the 33 patients who received postoperative oral contraceptives versus 1 (2.9%) recurrence in the 35 patients in the control group (not significant). The moderate-to-severe pain recurrence rate was 9.1% in the oral contraceptive group versus 17.1% in the control group (not significant). The mean time to recurrence of either symptoms or endometriomas was 18.2 months in the oral contraceptive group versus 12.7 months in the control group. The 12-month cumulative recurrence rate at life-table analysis was significantly lower for patients receiving oral contraceptives versus control subjects, whereas no significant difference was evident at 24 and 36 months. CONCLUSION: Postoperative administration of low-dose cyclic oral contraceptives does not significantly affect the long-term recurrence rate of endometriosis after surgical treatment. A delay in recurrence is evident at life-table analysis.


Subject(s)
Contraceptives, Oral, Combined/adverse effects , Endometriosis/surgery , Laparoscopy , Ovarian Diseases/surgery , Adult , Contraceptives, Oral, Combined/administration & dosage , Endometriosis/diagnostic imaging , Female , Humans , Ovarian Diseases/diagnostic imaging , Pain , Postoperative Period , Prospective Studies , Recurrence , Time Factors , Ultrasonography
19.
Eur J Surg ; 166(7): 552-6, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10965834

ABSTRACT

OBJECTIVE: To examine a possible association between tumour angiogenesis and conventional prognostic variables and to assess the prognostic value of the variables examined in patients with colorectal cancer, with no involved nodes. DESIGN: Retrospective study. SETTING: University hospital, Italy. SUBJECTS: 119 patients who had had colorectal cancers resected for cure with no involved nodes between 1985-1990. INTERVENTIONS: The three microscopic fields with the most microvessels were identified by immunohistochemical techniques. 10 high-power fields in each area were used for the microvessel count and the mean values indicated the microvessel density. MAIN OUTCOME MEASURES: Correlation of microvessel density with conventional prognostic factors, recurrence rates, and survival. RESULTS: There was a significant correlation between microvessel density and sex, women having a higher density than men (p < 0.05), but no significant correlations between density and recurrence rates or survival. Multivariate analysis did not indicate that microvessel density had a prognostic role. CONCLUSION: Microvessel density in colorectal cancer without involved nodes does not correlate with conventional prognostic factors and provides no prognostic information.


Subject(s)
Colorectal Neoplasms/pathology , Neovascularization, Pathologic , Aged , Analysis of Variance , Colorectal Neoplasms/blood supply , Colorectal Neoplasms/mortality , Female , Humans , Male , Microcirculation , Middle Aged , Neoplasm Staging , Prognosis , Recurrence , Retrospective Studies , Survival Analysis
20.
Brain ; 123 ( Pt 7): 1471-80, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10869058

ABSTRACT

The aim of this work was, first, to clarify the nature of the relationship between the sensory deficit in the demyelinated visual pathway and morphological changes revealed by MRI and, secondly, to test whether there was a preferential effect of demyelination for either the magnocellular or parvocellular pathway in established multiple sclerosis. Twenty-four patients with secondary progressive multiple sclerosis were studied psychophysically and by MRI of the optic nerve and brain. MRI was performed with a Phillips (0.5T) scanner. Visual pathway MRI lesion load was evaluated independently using the total optic nerve lesion length and lesion area seen on STIR (short inversion time inversion recovery) images of the optic nerve and the total post-chiasmal lesion area on T(1)-, T(2)- and proton-density-weighted images of the brain. Psychophysical tests determined 75%-seeing thresholds for horizontal gratings consisting of isoluminant red and green sinusoids of the same spatial frequency combined out-of-phase for preferential stimulation of the parvocellular system and in-phase for preferential stimulation of the magnocellular system. It was found that, in this group of patients, visual psychophysical loss was significantly correlated with lesion area seen on proton density MRI sequences of the post-chiasmal visual pathway, and that the parvocellular pathway was more affected than the magnocellular pathway, especially at lower spatial frequencies.


Subject(s)
Multiple Sclerosis, Chronic Progressive/pathology , Multiple Sclerosis, Chronic Progressive/physiopathology , Perceptual Disorders/pathology , Perceptual Disorders/physiopathology , Visual Perception/physiology , Adolescent , Adult , Brain/pathology , Brain/physiopathology , Evoked Potentials, Visual/physiology , Female , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Multiple Sclerosis, Chronic Progressive/complications , Optic Chiasm/pathology , Optic Chiasm/physiopathology , Optic Nerve/pathology , Optic Nerve/physiopathology , Perceptual Disorders/etiology , Psychophysics , Sensory Thresholds/physiology , Visual Acuity/physiology , Visual Fields/physiology , Visual Pathways/pathology , Visual Pathways/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...